Pharmaceutical

Century secures $60m in stock sale and buys preclinical cell therapy biotech

Century Therapeutics will pay $35m upfront and an additional $10m milestone payments to acquire Clade Therapeutics.

Apr 13, 2024 - 00:00
Century secures $60m in stock sale and buys preclinical cell therapy biotech
Century Therapeutics will pay $35m upfront and an additional $10m milestone payments to acquire Clade Therapeutics.
Read the original article

Tags:

Previous Article

Candel wins FDA orphan drug designation for pancreatic cancer drug

Next Article

Moderna pauses plans to build mRNA facility in Kenya

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AD/PD 2024: exploring cutting-edge therapies for ALS

AD/PD 2024: exploring cutting-edge therapies for ALS

Mar 9, 2024

Kezar stalls solid tumour trial to focus on autoimmune disease candidate

Kezar stalls solid tumour trial to focus on autoimmune ...

Aug 15, 2024

STAT+: Like a vampire, some cancer cells can suck the energy source from immune cells

STAT+: Like a vampire, some cancer cells can suck the e...

Oct 14, 2023